Volume 33, Issue 1 (11-2023)                   J Mazandaran Univ Med Sci 2023, 33(1): 77-85 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hassannia H, Enderami S E, Mansour R N, Eftekhary M, Abazari M, salarinia R. Design and Development of a Pseudotyped-lentivirus for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). J Mazandaran Univ Med Sci 2023; 33 (1) :77-85
URL: http://jmums.mazums.ac.ir/article-1-20074-en.html
Abstract:   (368 Views)
Background and purpose: Pseudoviruses, due to their immunity and adaptability, are valuable tools for developing vaccines and therapeutic drugs, particularly for emerging viruses. SARS-CoV-2, due to its high mortality rate and ease of transmission, should be handled under Biosafety Level 3 conditions, making the development of vaccines and therapeutic drugs challenging in many research centers. The present study aimed to produce a lentivirus pseudotype that can be used in neutralization assays based on pseudovirus under Biosafety Level 2 conditions.
Materials and methods: The SARS-CoV-2 Spike protein gene was inserted into the HIV-1 genome. Confirmation of entry was obtained through flow cytometry, electron microscopy, and immunofluorescence. Finally, the neutralization capacity of convalescent COVID-19 patients' sera was measured using the pseudovirus-based neutralization assay.
Results: The results of flow cytometry, electron microscopy, and immunofluorescence confirmed the entry of the Spike gene. Furthermore, the sera of convalescent patients showed significantly higher neutralizing capacity compared to the control group that had not been exposed to SARS-CoV-2.
Conclusion: The results of this study demonstrated that the use of the produced lentivirus pseudotype can measure the neutralizing capacity of patients' sera, and the pseudovirus-based neutralization assay serves as a suitable alternative for assessing the neutralization of live SARS-CoV-2. Moreover, this test can effectively evaluate vaccines or therapeutic drugs for combating this deadly virus.
 
Full-Text [PDF 947 kb]   (156 Downloads)    
Type of Study: Research(Original) | Subject: Biotechnology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Mazandaran University of Medical Sciences

Designed & Developed by : Yektaweb